Imbalance of Immunological Synapse-kinapse States Reflects Tumor Escape to Immunity in Glioblastoma
Overview
General Medicine
Authors
Affiliations
Since the proper activation of T cells requires the physical interaction with target cells through the formation of immunological synapses (IS), an alteration at this level could be a reason why tumors escape the immune response. As part of their life cycle, it is thought that T cells alternate between a static phase, the IS, and a dynamic phase, the immunological kinapse (IK), depending on high or low antigen sensing. Our investigation performed in tissue samples of human glioma shows that T cells are able to establish synapsing interactions not only with glioma tumorigenic cells, but also with stromal myeloid cells. Particularly, the IS displaying a T cell receptor-rich (TCR-rich) central supramolecular activation cluster (cSMAC) is preferentially established with stromal cells, as opposed to malignant cells. Conversely, T cells in the malignant areas showed distinct morphometric parameters compared with nonneoplastic tissue - the former characterized by an elongated shape, well-suited to kinaptic dynamics. Importantly, high-resolution 3-dimensional analyses demonstrated the existence of bona-fide IK preferentially arranged in malignant areas of the tumor. This imbalance of IS/IK states between these 2 microenvironments reveals the low antigenic sensing of T cells when patrolling tumorigenic cells and reflects the immunoevasive environment of the tumor.
Mastrogiovanni M, Donnadieu E, Pathak R, Di Bartolo V Biology (Basel). 2024; 13(11).
PMID: 39596815 PMC: 11591779. DOI: 10.3390/biology13110860.
De Luca C, Virtuoso A, Papa M, Cirillo G, La Rocca G, Corvino S Cells. 2024; 13(21.
PMID: 39513861 PMC: 11544881. DOI: 10.3390/cells13211754.
Boushehri S, Essig K, Chlis N, Herter S, Bacac M, Theis F Nat Commun. 2023; 14(1):7888.
PMID: 38036503 PMC: 10689847. DOI: 10.1038/s41467-023-43429-2.
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.
Qi T, Liao X, Cao Y Trends Pharmacol Sci. 2023; 44(12):880-890.
PMID: 37852906 PMC: 10843027. DOI: 10.1016/j.tips.2023.09.009.
Innate immune response restarts adaptive immune response in tumors.
Li W, Zhang Q, Li Q, Liu S, Yuan G, Pan Y Front Immunol. 2023; 14:1260705.
PMID: 37781382 PMC: 10538570. DOI: 10.3389/fimmu.2023.1260705.